Latest1 information on COVID-19

A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis

Not Recruiting

Trial ID: NCT00724334

Age - 18 Years-N/A Condition - Blood and Marrow Transplant (BMT), Myeloproliferative Neoplasm (MPN) Gender - All Accepting Healthy Volunteers - No

Purpose

The purpose of this study is to evaluate the long-term effects of orally administered SAR302503 (TG101348) in patients with myelofibrosis who have completed the MF-TG101348-001 study.

Official Title

An Open-Label Study to Evaluate the Long-Term Effects of Orally Administered SAR302503 in Patients With Primary or Secondary Myelofibrosis

Stanford Investigator(s)

Jason Gotlib

Professor of Medicine (Hematology)

Eligibility


Inclusion Criteria:

   - Completion of MF-TG101348-001 study

   - Diagnosis of myelofibrosis

   - At least 18 years of age

Exclusion Criteria:

   - Any acute or chronic medical abnormality that may increase the risk associated with
   study participation

View More
View Less

Intervention(s):

drug: SAR302503 (TG101348)

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office
650-498-7061

New Trial Alerts

Receive email alerts when trials open to patients.

©2022 Stanford Medicine